Jon K.
- Country
- Sweden
- Department
- Onkologiska kliniken
Research Overview
- Long-Term Safety Evaluation of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Prostate Cancer Patients: A Phase IV Post-Authorization Study
- A Phase 3 Randomized, Open-label Study of Opevesostat Tosylate Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
- Phase III Randomized Study of 177Lu-PSMA-617 with Standard of Care vs. Standard of Care in Metastatic Hormone-Sensitive Prostate Cancer
Data & Insights
Has run more than one trial at 117 of 261 partner sites.
Specializations
Advanced Prostate Cancer Management
This investigator specializes in treating metastatic castration-resistant prostate cancer (mCRPC) and hormone-sensitive prostate cancer, with particular focus on innovative therapeutic approaches.
- Post-surgical recurrence management
- Radiographic progression monitoring
- Hormone therapy resistance
Their expertise extends to biochemical recurrence interventions following prostate cancer surgery.
Nuclear Medicine Applications
The investigator has developed significant expertise in radioligand therapy, particularly focusing on Lutetium-based treatments for advanced prostate cancer.
- PSMA-targeted therapies
- Radiopharmaceutical safety monitoring
- Long-term treatment outcomes
Their work includes evaluation of novel nuclear medicine approaches in treatment-resistant cases.
Diagnostic Imaging Innovation
The investigator employs advanced imaging techniques, particularly PSMA PET/CT assessments, for treatment planning and monitoring in prostate cancer care.
- Individualized treatment planning
- Disease progression assessment
- Therapeutic response monitoring
Their approach integrates diagnostic imaging for precision-guided therapeutic interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.